Cardiovascular Medicine

6 pages, 191 KB

Open AccessCommunication

Checkliste für das perioperative Management von Schrittmacher- und ICD-Patienten

by Peter Zwicky, Haran Burri, Beat Schär, Nicola Schwick, Urs Bauersfeld, Istvan Babotai, Jürg Fuhrer, Hans O. Gloor, Jürg Schläpfer and Christian Sticherling

Cardiovasc. Med. 2010, 13(5), 177; https://doi.org/10.4414/cvm.2010.01498 - 26 May 2010

Viewed by 8

Abstract

A considerable number of patients with implanted pacemakers or ICDs (implantable cardioverter-defibrillators) undergo surgical procedures, which exposes them to different mechanical and electromagnetic threats [...] Full article

1 pages, 92 KB

Open AccessCommunication

Research Prize of the Swiss Heart Foundation

by Swiss Heart Foundation

Cardiovasc. Med. 2010, 13(5), 176; https://doi.org/10.4414/cvm.2010.01499 - 26 May 2010

Viewed by 5

Abstract

The Swiss Heart Foundation (SHF) awards an annual prize of 20 000 Swiss francs for one or more outstanding scientific research publications/accepted manuscripts in the field of prevention [...] Full article

2 pages, 383 KB

Open AccessInteresting Images

Intramyocardial Haemorrhage

by Stephan Schneiter and Andrew J. Taylor

Cardiovasc. Med. 2010, 13(5), 174; https://doi.org/cvm.2010.01504 - 26 May 2010

Viewed by 18

Abstract

A 59-year-old male patient presented with chest pain and electrocardiographic features of an acute inferolateral myocardial infarction [...] Full article

3 pages, 250 KB

Open AccessCase Report

Comprehensive “One Stop-Shop” Percutaneous Cardiac Intervention

by Thomas Pilgrim, Peter Wenaweser, Stephan Windecker and Bernhard Meier

Cardiovasc. Med. 2010, 13(5), 171; https://doi.org/10.4414/cvm.2010.01497 - 26 May 2010

Viewed by 7

Abstract

A 78-year-old male retired mathematician with severe aortic stenosis, persistant atrial fibrillation, reluctance to accept oral anticoagulation, and with suspected coronary artery disease was referred for further management [...] Full article

4 pages, 888 KB

Open AccessArticle

Muscular Ventricular Septal Defect After Mitral and Aortic Valve Replacement

by Augusto Aragão, Dorothea Vogel and Christoph Schmidt

Cardiovasc. Med. 2010, 13(5), 167; https://doi.org/10.4414/cvm.2010.01500 - 26 May 2010

Viewed by 13

Abstract

We describe a case series of five patients who were referred to our cardiac rehabilitation department after mitral or aortic valve replacement, and whose transthoracic echocardiographic studies showed postoperative muscular septal defects. Full article

7 pages, 158 KB

Open AccessArticle

Impact of Comorbidities on Clinical Presentation, Management and Outcome of Patients with Acute Coronary Syndrome

by Amir-Ali Fassa, Philip Urban, Dragana Radovanovic, Franz Eberli, Ralf Polikar, Jean-Christophe Stauffer, Osmund Bertel and Paul Erne

Cardiovasc. Med. 2010, 13(5), 155; https://doi.org/10.4414/cvm.2010.01502 - 26 May 2010

Cited by 1 | Viewed by 17

Abstract

Background: Most randomised controlled trials (RCT) for acute coronary syndrome (ACS) exclude patients with significant comorbidities. This may lead to misconceptions regarding applicable treatment modalities and hospital outcomes. The objective of the present analysis was to assess the importance of major comorbidities in [...] Read more.

Background: Most randomised controlled trials (RCT) for acute coronary syndrome (ACS) exclude patients with significant comorbidities. This may lead to misconceptions regarding applicable treatment modalities and hospital outcomes. The objective of the present analysis was to assess the importance of major comorbidities in patients admitted with ACS. Methods and results: We used the Charlson comorbidity Index (CCI) to evaluate the impact of chronic comorbidities in 19 496 patients included in the AMIS Plus registry following admission for ACS to 63 Swiss hospitals between 2002 and 2008. Among the studied population, 3881 (19.9%) had at least one comorbidity which would exclude them from most RCT for ACS. When compared to patients with a CCI score of 0, those with higher CCI scores were older, more frequently females, and had higher rates of hypertension, dyslipidaemia and obesity. They were less often treated with guideline-recommended drugs and eligible patients underwent acute reperfusion therapy less frequently. The CCI was associated with an increased rate of in-hospital mortality (3.0%, 5.6%, 8.1% and 13.7% respectively for a CCI score of 0, 1, 2, and 3 or more, p <0.001), and remained a powerful predictor of hospital mortality by multivariate analysis. For 3323 patients with long term follow-up, mortality 1 year after discharge was similarly correlated with the CCI (1.6%, 2.7%, 8.4%, and 16.0% respectively for a CCI score of 0, 1, 2, and 3 or more, p <0.001). Conclusions: Comorbidities have a major impact on clinical presentation, management and outcome of patients admitted to hospital for ACS. This should be taken into account when transposing results obtained from RCT into the “real world”. Full article

8 pages, 173 KB

Open AccessReview

Cardiovascular Drug Interactions with Tyrosine Kinase Inhibitors

by Amina Haouala, Nicolas Widmer, Michael Montemurro, Thierry Buclin and Laurent Decosterd

Cardiovasc. Med. 2010, 13(5), 147; https://doi.org/cvm.2010.01503 - 26 May 2010

Viewed by 14

Abstract

Imatinib mesylate, a selective inhibitor of tyrosine kinases, has excellent efficacy in the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumour (GIST). Inducing durable responses and achieving prolonged survival, it has become the standard of care for the treatment of these [...] Read more.

Imatinib mesylate, a selective inhibitor of tyrosine kinases, has excellent efficacy in the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumour (GIST). Inducing durable responses and achieving prolonged survival, it has become the standard of care for the treatment of these diseases. It has opened the way to the development of additional tyrosine kinase inhibitors (TKIs), including sunitinib, nilotinib, dasatinib and sorafenib, all indicated for the treatment of various haematological malignancies and solid tumours. TKIs are prescribed for prolonged periods and are often taken by patients with–notably cardiovascular–comorbidities. Hence TKIs are regularly co-administered with cardiovascular drugs, with a considerable risk of potentially harmful drug-drug interactions due to the large number of agents used in combination. However, this aspect has received limited attention so far, and a comprehensive review of the published data on this important topic has been lacking. We review here the available data and pharmacological mechanisms of interactions between commonly prescribed cardiovascular drugs and the TKIs marketed at present. Regular updating of the literature on this topic will be mandatory, as will the prospective reporting of unexpected clinical observations, given the fact that these drugs have been only recently marketed. Full article

Journal Menu

Journal Browser

Cardiovasc. Med., Volume 13, Issue 5 (05 2010) – 7 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI